French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC)

Background: Unresectable carcinomas of the oropharynx and hypopharynx still have a poor long-term prognosis. Following a previous phase II study, this phase III multicenter trial was conducted between November 1997 and March 2002.

Methods: Nontreated, strictly unresectable cases were eligible. Twice-daily radiation: two fractions of 1.2 Gy/day, 5 days per week, with no split (D1→D46). Total tumor doses: 80.4 Gy/46 day (oropharynx), 75.6 Gy/44 day (hypopharynx). Chemotherapy (arm B): Cisplatin 100 mg/m² (D1, D22, D43); 5FU, continuous infusion (D1→D5), 750 mg/m²/day cycle 1; 430 mg/m²/day cycles 2 and 3.

Results: A total of 163 evaluable patients. Grade 3–4 acute mucositis 82.6% arm B/69.5% arm A (NS); Grade 3–4 neutropenia 33.3% arm B/2.4% arm A (p < 0.05). Enteral nutrition through gastrostomy tube was more frequent in arm B before treatment and at 6 months (p < 0.01). At 24 months, overall survival (OS), disease-free survival (DFS), and specific survival (SS) were significantly better in arm B. OS: 37.8% arm B vs. 20.1% arm A (p = 0.038); DFS: 48.2% vs. 25.2% (p = 0.002); SS: 44.5% vs. 30.2% (p = 0.021). No significant difference between the two arms in the amount of side effects at 1 and 2 years.

Conclusion: For these unresectable cases, chemoradiation provides better outcome than radiation alone, even with an “aggressive” dose-intensity radiotherapy schedule.

Keywords:  Oropharynx carcinoma , Hypopharynx carcinoma , Chemoradiation , Twice-daily radiotherapy , Phase III prospective clinical trial